Risk factors for piperacillin/tazobactam-resistant Escherichia coli in ICU patients: A clinical study

Intensive Care Medicine

Volumn 29, Issue 7, 2003, Pages 1164-1168

  Mohammedi, Ismaël ^a   Ploin, Dominique ^a   Duperret, Serge ^a   Chapuis, François ^a   Petit, Paul ^a  

^a UNIVERSITÉ LYON 1   (France)

Author keywords

Critical care; Escherichia coli; Infection; Piperacillin tazobactam

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CEPHALOSPORIN DERIVATIVE; METRONIDAZOLE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM CULTURE; ESCHERICHIA COLI; FEMALE; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; NONHUMAN; RISK FACTOR;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MICROBIAL; ESCHERICHIA COLI; FRANCE; HUMANS; INTENSIVE CARE UNITS; PENICILLANIC ACID; PIPERACILLIN; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 0043168183     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00134-003-1760-9     Document Type: Article

References (15)

1. Bukharie HA, Abdelhadi MS, Saeed IA, Rubaish AM, Larbi EB (2001) Emergence of methicillin-resistant S. aureus as a community pathogen. Diagn Microbiol Infect Dis 40:1-4
2. Kaye KS, Harris AD, Gold H, Carmeli Y (2000) Risk factors for recovery of ampicillin-sulbactam-resistant E. coli in hospitalized patients. Antimicrob Agents Chemother 44:1004-1009
3. Cheong HJ, Yoo CW, Sohn JW, Kim WJ, Kim MJ, Park SC (2001) Bacteremia due to quinolone-resistant Escherichia coli in a teaching hospital in South Korea. Clin Infect Dis 33:48-53
4. Mohammedi I, Tigaud S, Tournadre JP (2000) Emergence of piperacillin/tazobactam-resistant Escherichia coli. Intensive Care Med 26:1584
5. Diekema DJ, Pfaller MA, Jones RN, Doern GV, Winokur PL, Gales AC, Sader HS, Kugler K, Beach M (1999) Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997. Clin Infect Dis 29:595-607
6. Lepelletier D, Caroff N, Reynaud A, Richet H (1999) Escherichia coli: epidemiology and analysis of risk factors for infections caused by resistant strains. Clin Infect Dis 29:548-552
7. Sotto A, De Boever CM, Fabbro-Peray P, Gouby A, Sirot D, Jourdan J (2001) Risk factors for antibiotic-resistant Escherichia coli isolated from hospitalized patients with urinary tract infections: a prospective study. J Clin Microbiol 39:438-444
8. Johnson CC, Baldessarre J, Levison ME (1997) Peritonitis: update on pathophysiology, clinical manifestattons, and management. Clin Infect Dis 24:1035-1045
9. Brismar B, Malmborg AS, Tunevall G, Wretlind B, Bergman L, Mentzing LO, Nystrom PO, kihlstrom E, Backstrand B, Skau T (1992) Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections. Antimicrob Agents Chemother 36:2766-2773
10. Dupont H, Carbon C, Carlet J (2000) Monotherapy with a broad-spectrum beta-lactam is as effective as its combination with an aminoglycoside in treatment of severe generalized peritonitis: a multicenter randomized controlled trial. Antimicrob Agents Chemother 44:2028-2033
11. Rello J, Torres A, Ricart M, Valles J, Gonzalez J, Artigas A, Rodriguez-Roisin R (1994) Ventilator associated pneumonia by Staphylococcus aureus: comparison of methicillin resistant and methicillin sensitive episodes. Am J Respir Crit Care Med 150:1545-1549
12. Trouillet JL, Vuagnat A, Combes A, Kassis N, Chastre J, Gibert C (2002) Pseudomonas aeruginosa ventilator associated pneumonia: comparison of piperacillin resistant and piperacillin susceptible organisms. Clin Infect Dis 34:1047-1054
13. Garau J, Xercavins M, Rodriguez-Carballeira M, Gomez-Vera JR, Coll I, Vidal D, Llovet T, Ruiz-Bremon A (1999) Emergence and dissemination of quinolone-resistant Escherichia coli in the community. Antimicrob Agents Chemother 43:2736-2741
14. Leflon-Guibout V, Ternat G, Heym B, Nicolas-Chanoine MH (2002) Exposure to co-amoxiclav as a risk factor for co-amoxiclav-resistant Escherichia coli urinary tract infection. J Antimicrob Chemother 49:367-371
15. Stapleton P, Wu PJ, King A, Shannon K, French G, Phillips I (1995) Incidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli. Antimicrob Agents Chemother 39:2478-2483